References
Rous, P. & Oliver, J. J. Exp. Med. 28, 696 (1910).
Hunter, T. & Sefton, B. Proc. Natl. Acad. Sci. USA 77, 1311–1315 (1980).
Downward, J. et al. Nature 307, 521 (1984).
Doolittle, R.F. et al. Science 221, 275–277 (1983).
Waterfield, M.D. et al. Nature 304, 35 (1983).
Nowell, P.C. & Hungerford, D.A. Science 142, 1497 (1960).
Rowley, J.D. Nature 243, 290–293 (1973).
Castagna, M. et al. J. Biol. Chem. 257, 7847–7851 (1982).
Hunter, T. Sci. Am. 251, 70–79 (1984).
Hanks, S.K. et al. Science 241, 42–52 (1988).
Hunter, T. Cell 50, 823–829 (1987).
Blume-Jensen, P. & Hunter, T. Nature 411, 355 (2001).
Foulkes, J.G. et al. J. Biol. Chem. 260, 8070–8077 (1985).
Lydon, N.B. et al. Oncogene Res. 5, 161–173 (1990).
Lydon, N.B. et al. Biochem. J. 287, 985–993 (1992).
McGlynn, E. et al. in Baculovirus and recombinant protein production processes. (eds. Vlak, J.M., Bernard, A. and Schaeger, E.-J.) 209–216 (Editiones Roche, Basel, 1992).
McGlynn, E. et al. J. Cell. Biochem. 49, 239–250 (1992).
McGlynn, E. et al. Eur. J. Biochem. 207, 265–275 (1992).
Druker, B.J. et al. N. Engl. J. Med. 321, 1383–1391 (1989).
Farley, K., Mett, H., McGlynn, E., Murray, B. & Lydon, N.B. Anal. Biochem. 203, 151–157 (1992).
Cohen, P. Nat. Rev. Drug Discov. 1, 309 (2002).
Levitzki, A. FASEB J. 6, 3275 (1992).
Traxler, P. Exp. Opin. Ther. Pat. 7, 571–588 (1997).
Umezawa, H. et al. J. Antibiot. 39, 170–173 (1986).
Graziani, Y. et al. Biochim. Biophys. Acta 714, 415–421 (1982).
Tamaoki, T. et al. Biochem. Biophys. Res. Commun. 135, 397–402 (1986).
Geissler, J.F. et al. Cancer Res. 56, 100–104 (1996).
Karaman, M.W. et al. Nat. Biotechnol. 26, 127 (2008).
Yaish, P. et al. Science 242, 933–935 (1988).
Zimmermann, J. et al. Arch. Pharm. Pharm. Med. Chem. 329, 371–376 (1996).
Zimmermann, J. et al. Bioorg. Med. Chem. Lett. 6, 1221–1226 (1996).
Buchdunger, E. et al. Cancer Res. 56, 100–104 (1996).
Knighton, D.R. et al. Science 253, 407–414 (1991).
Druker, B.J. & Lydon, N.B. J. Clin. Invest. 105, 3–7 (2000).
Schindler, T. et al. Science 289, 1938–1942 (2000).
Huse, M. & Kuriyan, J. Cell 109, 275 (2002).
Fabian, M.A. et al. Nat. Biotechnol. 23, 329 (2005).
Druker, B.J. et al. Nat. Med. 2, 561–566 (1996).
Carroll, M. et al. Blood 90, 4947–4952 (1997).
Heinrich, M.C. et al. Blood 96, 925–932 (2000).
Buchdunger, E. et al. J. Pharmacol. Exp. Ther. 295, 139–145 (2000).
Demetri, G.D. et al. N. Engl. J. Med. 347, 472–480 (2002).
Druker, B.J. et al. N. Engl. J. Med. 344, 1031–1037 (2001).
Heinrich, M.C., Blanke, C.D., Druker, B.J. & Corless, C.L. J. Clin. Oncol. 20, 1692–1703 (2002).
Siddiqui, M.A. & Scott, L.J. Drugs 67, 805–820 (2007).
Golub, T.R., Barker, G.F., Lovett, M. & Gilliland, D.G. Cell 77, 307–316 (1994).
Apperley, J.F. et al. N. Engl. J. Med. 347, 481–487 (2002).
Magnusson, M.K., Meade, K.E., Nakamura, R., Barrett, J. & Dunbar, C.E. Blood 100, 1088–1091 (2002).
Gleich, G.J., Leiferman, K.M., Pardanani, A., Tefferi, A. & Butterfield, J.H. Lancet 359, 1577–1578 (2002).
Cools, J. et al. N. Engl. J. Med. 348, 1201–1214 (2003).
Herbst, R.S. et al. Nat. Rev. Cancer 4, 956 (2004).
Arteaga, C.L. Nat. Med. 10, 577 (2004).
Kris, M.G. J. Am. Med. Assoc. 290, 2149–2158 (2003).
Paez, J.G. et al. Science 304, 1497–1500 (2004).
Lynch, T.J. N. Engl. J. Med. 350, 2129–2139 (2004).
Pao, W. et al. Proc. Natl. Acad. Sci. USA 101, 13306–13311 (2004).
Pao, W. et al. PLoS Med. 2, e73 (2005).
Kobayashi, S. et al. N. Engl. J. Med. 352, 786–792 (2005).
Gorre, M.E. et al. Science 293, 876–880 (2001).
Hanahan, D. & Weinberg, R.A. Cell 100, 57 (2000).
Liu, Y. & Grey, N.S. Nat. Chem. Biol. 2, 358–364 (2006).
Wedge, S.R. et al. Cancer Res. 62, 4645–4655 (2002).
Heymach, J.V. Br. J. Cancer 92, S14–S20 (2005).
Goldstein, D.M. et al. Nat. Rev. Drug Discov. 7, 391 (2008).
Acknowledgements
I am grateful to the many people who have participated in the imatanib project, including my former laboratory staff and research and development colleagues at Ciba-Geigy (Novartis), and the many clinical scientists involved in the imatinib clinical program. I would like to acknowledge the major contributions made by E. Buchdunger, B. Druker, H. Mett, P. Traxler and J. Zimmermann. I would also like to acknowledge the support and mentoring of A. Matter and G. Haas during my time at Ciba-Geigy and T. Roberts and B. Hemmings for their support and scientific advice. I would like to thank P. Zarrinker for providing Figures 5 and 6.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
N.L. is a Science Advisory Board member for Ambit Biosciences, and he is an owner of stock in Ambit.
Rights and permissions
About this article
Cite this article
Lydon, N. Attacking cancer at its foundation. Nat Med 15, 1153–1157 (2009). https://doi.org/10.1038/nm1009-1153
Issue Date:
DOI: https://doi.org/10.1038/nm1009-1153
- Springer Nature America, Inc.
This article is cited by
-
Targeted therapy: resistance and re-sensitization
Chinese Journal of Cancer (2015)
-
The molecular pathology of cancer
Nature Reviews Clinical Oncology (2010)